Recently stock market analysts have updated their consensus ratings on shares of Bellicum Pharmaceuticals, Inc. (BLCM). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/15/2016 – Bellicum Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 19 price target on the stock.

02/25/2016 – Citigroup began new coverage on Bellicum Pharmaceuticals, Inc. giving the company a “neutral” rating. They now have a USD 11 price target on the stock.

12/18/2015 – Bellicum Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Piper Jaffray. They now have a USD 45 price target on the stock.

09/11/2015 – Bellicum Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Guggenheim. They now have a USD 38 price target on the stock.

04/30/2015 – Bellicum Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Zacks.

Bellicum Pharmaceuticals, Inc. has a 50 day moving average of 9.99 and a 200 day moving average of 13.72. The stock’s market capitalization is 242.75M, it has a 52-week low of 7.24 and a 52-week high of 29.33.

The share price of the company (BLCM) was up +3.27% during the last trading session, with a high of 9.26 and the volume of Bellicum Pharmaceuticals, Inc. shares traded was 383141.

View other investors thoughts on Bellicum Pharmaceuticals, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.